NEW YORK (GenomeWeb) – GenMark Diagnostics reported after the close of the market on Tuesday that its first quarter revenues rose 13 percent, driven by strong sales of its XT-8 molecular diagnostics system.

For the three months ended March 31, the molecular diagnostics firm reported revenues of $12.5 million, up from $11.1 million a year ago, and matching the consensus Wall Street estimate.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.